BioNTech’s Bold Gamble: Investment in Cancer Research Amidst Financial Challenges
BioNTech, known for its COVID-19 vaccine, is shifting focus towards mRNA-based cancer treatments, despite reporting a decline in earnings for Q4 2024. The company’s profit per share fell to €1.08,…